Hyperbaric oxygen and radiotherapy
Hyperbaric oxygen (HBO) therapy is the inhalation of 100% oxygen at a pressure of at least 1.5 atmospheres absolute (150 kPa). It uses oxygen as a drug by dissolving it in the plasma and delivering it to the tissues independent of hemoglobin. For a variety of organ systems, HBO is known to promote n...
Gespeichert in:
| Veröffentlicht in: | Strahlentherapie und Onkologie 2005-02, Vol.181 (2), p.113-123 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 123 |
|---|---|
| container_issue | 2 |
| container_start_page | 113 |
| container_title | Strahlentherapie und Onkologie |
| container_volume | 181 |
| creator | Mayer, Ramona Hamilton-Farrell, Martin R van der Kleij, Adrian J Schmutz, Jörg Granström, Gösta Sicko, Zdzislaw Melamed, Yehuda Carl, Ulrich M Hartmann, K Axel Jansen, Erik C Ditri, Luciano Sminia, Peter |
| description | Hyperbaric oxygen (HBO) therapy is the inhalation of 100% oxygen at a pressure of at least 1.5 atmospheres absolute (150 kPa). It uses oxygen as a drug by dissolving it in the plasma and delivering it to the tissues independent of hemoglobin. For a variety of organ systems, HBO is known to promote new vessel growth into areas with reduced oxygen tension due to poor vascularity, and therewith promotes wound healing and recovery of radiation-injured tissue. Furthermore, tumors may be sensitized to irradiation by raising intratumoral oxygen tensions.
A network of hyperbaric facilities exists in Europe, and a number of clinical studies are ongoing. The intergovernmental framework COST B14 action "Hyperbaric Oxygen Therapy" started in 1999. The main goal of the Working Group Oncology is preparation and actual implementation of prospective study protocols in the field of HBO and radiation oncology in Europe.
In this paper a short overview on HBO is given and the following randomized clinical studies are presented: a) reirradiation of recurrent squamous cell carcinoma of the head and neck after HBO sensitization; b) role of HBO in enhancing radiosensitivity on glioblastoma multiforme; c) osseointegration in irradiated patients; adjunctive HBO to prevent implant failures; d) the role of HBO in the treatment of late irradiation sequelae in the pelvic region. The two radiosensitization protocols (a, b) allow a time interval between HBO and subsequent irradiation of 10-20 min.
Recruitment of centers and patients is being strongly encouraged, detailed information is given on www.oxynet.org. |
| doi_str_mv | 10.1007/s00066-005-1277-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67418552</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2226250831</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-49c9f4c9a7dc0ef12ecddbbf73d0d88394533b02e5986f4a511be0faf5b157ce3</originalsourceid><addsrcrecordid>eNpdkM1KAzEYRYMotlYfwI2ULtxFvy8_k8lSilqh4EbBXcjkR6e0MzXpgPP2TmlBcHU3514uh5BrhDsEUPcZAIqCAkiKTCnan5AxCq4paP1xSsaASlOFshyRi5xXAFgILc7JCKUCxgHGZLbotyFVNtVu2v70n6GZ2sZPk_V1u_sKyW77S3IW7TqHq2NOyPvT49t8QZevzy_zhyV1nBU7KrTTUThtlXcQIrLgvK-qqLgHX5ZcC8l5BSxIXRZRWIlYBYg2ymq44wKfkNvD7ja1313IO7OpswvrtW1C22VTKIGllGwAZ__AVdulZvhmSoaqFMiKAcID5FKbcwrRbFO9sak3CGZvzxzsmcGe2dsz_dC5OQ531Sb4v8ZRF_8FsdFp7A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>821784126</pqid></control><display><type>article</type><title>Hyperbaric oxygen and radiotherapy</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Mayer, Ramona ; Hamilton-Farrell, Martin R ; van der Kleij, Adrian J ; Schmutz, Jörg ; Granström, Gösta ; Sicko, Zdzislaw ; Melamed, Yehuda ; Carl, Ulrich M ; Hartmann, K Axel ; Jansen, Erik C ; Ditri, Luciano ; Sminia, Peter</creator><creatorcontrib>Mayer, Ramona ; Hamilton-Farrell, Martin R ; van der Kleij, Adrian J ; Schmutz, Jörg ; Granström, Gösta ; Sicko, Zdzislaw ; Melamed, Yehuda ; Carl, Ulrich M ; Hartmann, K Axel ; Jansen, Erik C ; Ditri, Luciano ; Sminia, Peter ; The European intergovernmental framework COST (European CO-operation in the field of Science and Technology research), COST B14 Working Group Oncology</creatorcontrib><description>Hyperbaric oxygen (HBO) therapy is the inhalation of 100% oxygen at a pressure of at least 1.5 atmospheres absolute (150 kPa). It uses oxygen as a drug by dissolving it in the plasma and delivering it to the tissues independent of hemoglobin. For a variety of organ systems, HBO is known to promote new vessel growth into areas with reduced oxygen tension due to poor vascularity, and therewith promotes wound healing and recovery of radiation-injured tissue. Furthermore, tumors may be sensitized to irradiation by raising intratumoral oxygen tensions.
A network of hyperbaric facilities exists in Europe, and a number of clinical studies are ongoing. The intergovernmental framework COST B14 action "Hyperbaric Oxygen Therapy" started in 1999. The main goal of the Working Group Oncology is preparation and actual implementation of prospective study protocols in the field of HBO and radiation oncology in Europe.
In this paper a short overview on HBO is given and the following randomized clinical studies are presented: a) reirradiation of recurrent squamous cell carcinoma of the head and neck after HBO sensitization; b) role of HBO in enhancing radiosensitivity on glioblastoma multiforme; c) osseointegration in irradiated patients; adjunctive HBO to prevent implant failures; d) the role of HBO in the treatment of late irradiation sequelae in the pelvic region. The two radiosensitization protocols (a, b) allow a time interval between HBO and subsequent irradiation of 10-20 min.
Recruitment of centers and patients is being strongly encouraged, detailed information is given on www.oxynet.org.</description><identifier>ISSN: 0179-7158</identifier><identifier>EISSN: 1439-099X</identifier><identifier>DOI: 10.1007/s00066-005-1277-y</identifier><identifier>PMID: 15702300</identifier><language>eng</language><publisher>Germany: Springer Nature B.V</publisher><subject>Cancer ; Combined Modality Therapy - methods ; Humans ; Hyperbaric Oxygenation - methods ; Neoplasms - therapy ; Oxygen therapy ; Radiation therapy ; Radiotherapy - methods ; Randomized Controlled Trials as Topic ; Treatment Outcome ; Wound healing</subject><ispartof>Strahlentherapie und Onkologie, 2005-02, Vol.181 (2), p.113-123</ispartof><rights>Urban & Vogel München 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c326t-49c9f4c9a7dc0ef12ecddbbf73d0d88394533b02e5986f4a511be0faf5b157ce3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15702300$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mayer, Ramona</creatorcontrib><creatorcontrib>Hamilton-Farrell, Martin R</creatorcontrib><creatorcontrib>van der Kleij, Adrian J</creatorcontrib><creatorcontrib>Schmutz, Jörg</creatorcontrib><creatorcontrib>Granström, Gösta</creatorcontrib><creatorcontrib>Sicko, Zdzislaw</creatorcontrib><creatorcontrib>Melamed, Yehuda</creatorcontrib><creatorcontrib>Carl, Ulrich M</creatorcontrib><creatorcontrib>Hartmann, K Axel</creatorcontrib><creatorcontrib>Jansen, Erik C</creatorcontrib><creatorcontrib>Ditri, Luciano</creatorcontrib><creatorcontrib>Sminia, Peter</creatorcontrib><creatorcontrib>The European intergovernmental framework COST (European CO-operation in the field of Science and Technology research), COST B14 Working Group Oncology</creatorcontrib><title>Hyperbaric oxygen and radiotherapy</title><title>Strahlentherapie und Onkologie</title><addtitle>Strahlenther Onkol</addtitle><description>Hyperbaric oxygen (HBO) therapy is the inhalation of 100% oxygen at a pressure of at least 1.5 atmospheres absolute (150 kPa). It uses oxygen as a drug by dissolving it in the plasma and delivering it to the tissues independent of hemoglobin. For a variety of organ systems, HBO is known to promote new vessel growth into areas with reduced oxygen tension due to poor vascularity, and therewith promotes wound healing and recovery of radiation-injured tissue. Furthermore, tumors may be sensitized to irradiation by raising intratumoral oxygen tensions.
A network of hyperbaric facilities exists in Europe, and a number of clinical studies are ongoing. The intergovernmental framework COST B14 action "Hyperbaric Oxygen Therapy" started in 1999. The main goal of the Working Group Oncology is preparation and actual implementation of prospective study protocols in the field of HBO and radiation oncology in Europe.
In this paper a short overview on HBO is given and the following randomized clinical studies are presented: a) reirradiation of recurrent squamous cell carcinoma of the head and neck after HBO sensitization; b) role of HBO in enhancing radiosensitivity on glioblastoma multiforme; c) osseointegration in irradiated patients; adjunctive HBO to prevent implant failures; d) the role of HBO in the treatment of late irradiation sequelae in the pelvic region. The two radiosensitization protocols (a, b) allow a time interval between HBO and subsequent irradiation of 10-20 min.
Recruitment of centers and patients is being strongly encouraged, detailed information is given on www.oxynet.org.</description><subject>Cancer</subject><subject>Combined Modality Therapy - methods</subject><subject>Humans</subject><subject>Hyperbaric Oxygenation - methods</subject><subject>Neoplasms - therapy</subject><subject>Oxygen therapy</subject><subject>Radiation therapy</subject><subject>Radiotherapy - methods</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Treatment Outcome</subject><subject>Wound healing</subject><issn>0179-7158</issn><issn>1439-099X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkM1KAzEYRYMotlYfwI2ULtxFvy8_k8lSilqh4EbBXcjkR6e0MzXpgPP2TmlBcHU3514uh5BrhDsEUPcZAIqCAkiKTCnan5AxCq4paP1xSsaASlOFshyRi5xXAFgILc7JCKUCxgHGZLbotyFVNtVu2v70n6GZ2sZPk_V1u_sKyW77S3IW7TqHq2NOyPvT49t8QZevzy_zhyV1nBU7KrTTUThtlXcQIrLgvK-qqLgHX5ZcC8l5BSxIXRZRWIlYBYg2ymq44wKfkNvD7ja1313IO7OpswvrtW1C22VTKIGllGwAZ__AVdulZvhmSoaqFMiKAcID5FKbcwrRbFO9sak3CGZvzxzsmcGe2dsz_dC5OQ531Sb4v8ZRF_8FsdFp7A</recordid><startdate>200502</startdate><enddate>200502</enddate><creator>Mayer, Ramona</creator><creator>Hamilton-Farrell, Martin R</creator><creator>van der Kleij, Adrian J</creator><creator>Schmutz, Jörg</creator><creator>Granström, Gösta</creator><creator>Sicko, Zdzislaw</creator><creator>Melamed, Yehuda</creator><creator>Carl, Ulrich M</creator><creator>Hartmann, K Axel</creator><creator>Jansen, Erik C</creator><creator>Ditri, Luciano</creator><creator>Sminia, Peter</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FG</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>200502</creationdate><title>Hyperbaric oxygen and radiotherapy</title><author>Mayer, Ramona ; Hamilton-Farrell, Martin R ; van der Kleij, Adrian J ; Schmutz, Jörg ; Granström, Gösta ; Sicko, Zdzislaw ; Melamed, Yehuda ; Carl, Ulrich M ; Hartmann, K Axel ; Jansen, Erik C ; Ditri, Luciano ; Sminia, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-49c9f4c9a7dc0ef12ecddbbf73d0d88394533b02e5986f4a511be0faf5b157ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Cancer</topic><topic>Combined Modality Therapy - methods</topic><topic>Humans</topic><topic>Hyperbaric Oxygenation - methods</topic><topic>Neoplasms - therapy</topic><topic>Oxygen therapy</topic><topic>Radiation therapy</topic><topic>Radiotherapy - methods</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Treatment Outcome</topic><topic>Wound healing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mayer, Ramona</creatorcontrib><creatorcontrib>Hamilton-Farrell, Martin R</creatorcontrib><creatorcontrib>van der Kleij, Adrian J</creatorcontrib><creatorcontrib>Schmutz, Jörg</creatorcontrib><creatorcontrib>Granström, Gösta</creatorcontrib><creatorcontrib>Sicko, Zdzislaw</creatorcontrib><creatorcontrib>Melamed, Yehuda</creatorcontrib><creatorcontrib>Carl, Ulrich M</creatorcontrib><creatorcontrib>Hartmann, K Axel</creatorcontrib><creatorcontrib>Jansen, Erik C</creatorcontrib><creatorcontrib>Ditri, Luciano</creatorcontrib><creatorcontrib>Sminia, Peter</creatorcontrib><creatorcontrib>The European intergovernmental framework COST (European CO-operation in the field of Science and Technology research), COST B14 Working Group Oncology</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Strahlentherapie und Onkologie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mayer, Ramona</au><au>Hamilton-Farrell, Martin R</au><au>van der Kleij, Adrian J</au><au>Schmutz, Jörg</au><au>Granström, Gösta</au><au>Sicko, Zdzislaw</au><au>Melamed, Yehuda</au><au>Carl, Ulrich M</au><au>Hartmann, K Axel</au><au>Jansen, Erik C</au><au>Ditri, Luciano</au><au>Sminia, Peter</au><aucorp>The European intergovernmental framework COST (European CO-operation in the field of Science and Technology research), COST B14 Working Group Oncology</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hyperbaric oxygen and radiotherapy</atitle><jtitle>Strahlentherapie und Onkologie</jtitle><addtitle>Strahlenther Onkol</addtitle><date>2005-02</date><risdate>2005</risdate><volume>181</volume><issue>2</issue><spage>113</spage><epage>123</epage><pages>113-123</pages><issn>0179-7158</issn><eissn>1439-099X</eissn><abstract>Hyperbaric oxygen (HBO) therapy is the inhalation of 100% oxygen at a pressure of at least 1.5 atmospheres absolute (150 kPa). It uses oxygen as a drug by dissolving it in the plasma and delivering it to the tissues independent of hemoglobin. For a variety of organ systems, HBO is known to promote new vessel growth into areas with reduced oxygen tension due to poor vascularity, and therewith promotes wound healing and recovery of radiation-injured tissue. Furthermore, tumors may be sensitized to irradiation by raising intratumoral oxygen tensions.
A network of hyperbaric facilities exists in Europe, and a number of clinical studies are ongoing. The intergovernmental framework COST B14 action "Hyperbaric Oxygen Therapy" started in 1999. The main goal of the Working Group Oncology is preparation and actual implementation of prospective study protocols in the field of HBO and radiation oncology in Europe.
In this paper a short overview on HBO is given and the following randomized clinical studies are presented: a) reirradiation of recurrent squamous cell carcinoma of the head and neck after HBO sensitization; b) role of HBO in enhancing radiosensitivity on glioblastoma multiforme; c) osseointegration in irradiated patients; adjunctive HBO to prevent implant failures; d) the role of HBO in the treatment of late irradiation sequelae in the pelvic region. The two radiosensitization protocols (a, b) allow a time interval between HBO and subsequent irradiation of 10-20 min.
Recruitment of centers and patients is being strongly encouraged, detailed information is given on www.oxynet.org.</abstract><cop>Germany</cop><pub>Springer Nature B.V</pub><pmid>15702300</pmid><doi>10.1007/s00066-005-1277-y</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0179-7158 |
| ispartof | Strahlentherapie und Onkologie, 2005-02, Vol.181 (2), p.113-123 |
| issn | 0179-7158 1439-099X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67418552 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Cancer Combined Modality Therapy - methods Humans Hyperbaric Oxygenation - methods Neoplasms - therapy Oxygen therapy Radiation therapy Radiotherapy - methods Randomized Controlled Trials as Topic Treatment Outcome Wound healing |
| title | Hyperbaric oxygen and radiotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T16%3A46%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hyperbaric%20oxygen%20and%20radiotherapy&rft.jtitle=Strahlentherapie%20und%20Onkologie&rft.au=Mayer,%20Ramona&rft.aucorp=The%20European%20intergovernmental%20framework%20COST%20(European%20CO-operation%20in%20the%20field%20of%20Science%20and%20Technology%20research),%20COST%20B14%20Working%20Group%20Oncology&rft.date=2005-02&rft.volume=181&rft.issue=2&rft.spage=113&rft.epage=123&rft.pages=113-123&rft.issn=0179-7158&rft.eissn=1439-099X&rft_id=info:doi/10.1007/s00066-005-1277-y&rft_dat=%3Cproquest_cross%3E2226250831%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=821784126&rft_id=info:pmid/15702300&rfr_iscdi=true |